Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Soma K, Bradley J, Mebus C; ORAL Step investigators. Burmester GR, et al. Among authors: mebus c. Lancet. 2013 Feb 9;381(9865):451-60. doi: 10.1016/S0140-6736(12)61424-X. Epub 2013 Jan 5. Lancet. 2013. PMID: 23294500 Clinical Trial.
Tofacitinib for rheumatoid arthritis - Authors' reply.
Burmester GR, Benda B, Gruben D, Bradley J, Mebus C. Burmester GR, et al. Among authors: mebus c. Lancet. 2013 May 25;381(9880):1812-3. doi: 10.1016/S0140-6736(13)61115-0. Lancet. 2013. PMID: 23706795 No abstract available.
Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials.
Rendas-Baum R, Kosinski M, Singh A, Mebus CA, Wilkinson BE, Wallenstein GV. Rendas-Baum R, et al. Among authors: mebus ca. Rheumatology (Oxford). 2017 Aug 1;56(8):1386-1394. doi: 10.1093/rheumatology/kex087. Rheumatology (Oxford). 2017. PMID: 28460083 Free PMC article. Clinical Trial.
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.
Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, Gomez-Reino J, Soma K, Mebus C, Wilkinson B, Hodge J, Fan H, Wang T, Bingham CO 3rd. Winthrop KL, et al. Among authors: mebus c. Ann Rheum Dis. 2016 Apr;75(4):687-95. doi: 10.1136/annrheumdis-2014-207191. Epub 2015 Mar 20. Ann Rheum Dis. 2016. PMID: 25795907 Free PMC article. Clinical Trial.
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.
Ruperto N, Brunner HI, Zuber Z, Tzaribachev N, Kingsbury DJ, Foeldvari I, Horneff G, Smolewska E, Vehe RK, Hazra A, Wang R, Mebus CA, Alvey C, Lamba M, Krishnaswami S, Stock TC, Wang M, Suehiro R, Martini A, Lovell DJ; Pediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Ruperto N, et al. Among authors: mebus ca. Pediatr Rheumatol Online J. 2017 Dec 28;15(1):86. doi: 10.1186/s12969-017-0212-y. Pediatr Rheumatol Online J. 2017. PMID: 29282090 Free PMC article. Clinical Trial.
Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight.
Hutmacher MM, Papp K, Krishnaswami S, Ito K, Tan H, Wolk R, Valdez H, Mebus C, Rottinghaus ST, Gupta P. Hutmacher MM, et al. Among authors: mebus c. CPT Pharmacometrics Syst Pharmacol. 2017 May;6(5):322-330. doi: 10.1002/psp4.12182. Epub 2017 Mar 20. CPT Pharmacometrics Syst Pharmacol. 2017. PMID: 28317328 Free PMC article. Clinical Trial.
140 results